"will they test the way ERES currently has the technology to perform testing?"
Yeah, I tend to think so.
eRT will perform digital collection, measurement, interpretation, review, and distribution of cardiac safety data through its EXPeRT workflow enabled data handling technology, the first solution in production that was designed explicitly to meet emerging international regulatory guidance and technical standards.
you really crack me up, but it does not surprise me. do you think it is as simple as the FDA requiring more testing? everybody knows there will be more cardiac safety testing. why do you assume that ERES benefits from it? will they test the way ERES currently has the technology to perform testing (you probably don't even know the difference)? you should do some homework before you run your mouth. if the whole premise of your investment is that there will be more cardiac safety testing and ERES MUST get that business, you will lose a lot of money. do you think you are the only one who knows this?